Index

A
ACSM. See American College of Sports Medicine (ACSM)
Activity Promotion (ACTION) trial, 222
Acute lymphocytic leukemia (ALL), 161–162
Adaptive immunity, 39
ADCC. See Antibody-dependent cell-mediated cytotoxicity (ADCC)
Adipokines, 31–32
Adiponectin, 23
ADT. See Androgen deprivation therapy (ADT)
Aerobic and resistance exercise, cancer survivors
ACSM guidelines, 201
body composition, 207–209
breast cancer-related lymphedema, 209–210
cancer specific and overall survival, 210–211
cardiorespiratory fitness, 206–207
CRF, 204–205
future prospects, 212
home-based programs, 212
physical activity recommendations, 200
QOL
breast cancer related effects, 203
efficacy improvement, 201–202
FACT survey, 201
influence of attention, 202–203
outcomes and future prospects, 203–204
yoga and, 203
Aerobic training, 202
Aging
balance and body composition, 187
skeletal muscle mass, 185–186
weight management
biologic mechanisms, 183
breast cancer, 183–184
diet and exercise trial, 184
energy restricted diets, 185
prevalence, 182
Weight Watchers® program, 184
WINS, 184–185
ALL. See Acute lymphocytic leukemia (ALL)
Allogeneic HSCT (Allo-HSCT), 120
Alternatively activated macrophages/M2 macrophages, 41
American College of Sports Medicine (ACSM), 108, 161, 201
AMP kinase (AMPK), 66
Anabolic signaling and exercise
AMPK paradox, 67–68
mTOR regulation, 66–67
Androgen deprivation therapy (ADT), 188–189
Anorexia, 60
Anorexia-cachexia syndrome, 152
 Anthracyclines, 111, 114
Antibodies, 39, 40
Antibody-dependent cell-mediated cytotoxicity (ADCC), 40
Antioxidant defense systems
distribution, 12–13
exercise-induced changes, 13–14
GPX, 11
GRX, 12
α-lipoic acid and bilirubin, 12
PRX, 12
SOD, 11
TRX, 12
uric acid, 12
APCMin+/−, 24
Autologous HSCT (Auto-HSCT), 120
Autophagy, 25–26

B
B-cells, 161, 162
Biological pathways and cancer survival
  cachexia (see Cachexia)
  exercise
    acute and chronic, 63–64
    definition, 61
    duration, 63
    guidelines, 64–65
    intensity, 62–63
    mode, 61–62
Bladder cancer, 94
Blood oxygenation, 165
B lymphocytes, 39
B16 melanoma, 24–25
Body composition, 207–209
Body mass index (BMI), 187, 208
Bone mineral density (BMD), 22, 208
Brain derived neurotrophic factor (BDNF), 25
Breast cancer, 89–90, 109–111, 209–210
Brief Fatigue Inventory (BFI), 128

C
Cachexia
  anabolic signaling and exercise
    AMPK paradox, 67–68
    mTOR regulation, 66–67
  catabolic signaling and exercise
    benefits, 70
    FOXO3 protein, 69
    protein degradation processes, 68–69
  clinical conditions, 60
  definition, 59
  exercise, 60–61
  insulin resistance and exercise, 74–75
  multiple stimuli, 65
  muscle mitochondria and exercise
    AMPK, mTOR, and FOXO, 71–72
    benefits, 72–73
    DRP1 and OPA1, 72
    muscle oxidative capacity, 70
    subsarcolemmal and intermyofibrillar
      populations, 70–71
  muscle protein degradation, 60
  prevalence, 60
  type II diabetes, 66
  Cancer control and exercise associated
    regulation
  constitutional and cancer specific
    benefits, 22
  human
    adipokines, 31–32
    cytokines, 32
    IGF system, 29–30
    immune system response factors, 32–33
    insulin, 27–29
    RCTs, 26–27
    sex steroid hormones, 30–31
  model system
    autophagy, 25–26
    BDNF, 25
    enriched environment, 24–25
    IGF-1 levels, 23
    insulin levels, 22
    intestinal polyp development, 24
    leptin levels, 23–24
    obesity, 22–23
    outcomes, 26
    PEPCK transgenic mice, 24
  Cancer progression, 22
  Cancer related fatigue (CRF), 22, 204–205
  Cancer specific survival, 210–211
  Cancer survival, 22
  Cancer survivors, exercise, 160, 164, 167
    future research, 224–225
    health outcomes, 216
    interest and ability, 218
    maintenance
      definition, 221
      efficacy, 222–224
      evidence, 221
    motivators and barriers, 218–219
    participation rates, 216–217
    practical implications, 225–226
    prevalence figures, 226–227
    social cognitive determinants, 219–220
  Cancer therapy and exercise
    aerobic interval training program, 110
    aerobic vs. resistance training, 115
    cardiac damage reduction, 114
    efficacy comparison, 111–112
    exercise intolerance, 109
    future prospects, 115
    group-based exercise training, 112
    impaired cardiorespiratory fitness, 108–109
    prevention paradigm, 108
    safety, feasibility, and efficacy
      examination, 112–113
    treadmill exercise, 110–111
    treatment-related toxicities, 113–114
Index

Cardiorespiratory fitness, 108–109, 206–207
Catabolic signaling and exercise benefits, 70
FOXO3 protein, 69
protein degradation processes, 68–69
Catalase (CAT), 11
CD8+ cytotoxic T cells, 40
CD4+ helper T lymphocytes, 40
CD4+ T helper cells, 39
Central nervous system (CNS) tumors, 163
Childhood cancer, 167–168
Colon cancer, 85–87
Concentric exercise, 186
Consolidation, 162
Coping style, 219
C reactive protein (CRP), 23
CRF. See Cancer related fatigue (CRF)
Cytokines, 32, 40–42

D
Delayed-type hypersensitivity (DTH), 48
Dendritic cells, 39
Diet induced obesity, 23, 25
Disease free survival, 191
Donor lymphocyte infusion (DLI), 120
Dual-energy x-ray absorptiometry (DXA), 188, 208
Dynamin related protein-1 (DRP1), 72

E
Eccentric exercise, 186
Elderly cancer survivors
aging balance and body composition, 187
skeletal muscle mass, 185–186
weight management (see Weight management)
body composition measurement, 187–188
breast cancer, body composition and survival, 189–190
consequences, 183
exercise recommendations, 191
prostate cancer and ADT, 188–189
Endometrial cancer, 90–91
Endurance exercise, 112
Enriched environment (EE), 24–25
Exercise and cancer (see Cancer therapy and exercise)
constitutional benefits, 22
duration, 63
intensity, 62–63
and pediatric cancer treatment (see Pediatric cancer treatment) training, 206, 207
Exercise, energy balance and cancer abnormalities, 1
conceptual and practical challenges, 3
NCT, 2
objectives, 3–4
risks and benefits, 1–2
transdisciplinary approach, 2
Exhaustive exercise, 8

F
Fas-FasL, 40
Fatalists, 219
Fatigue, 109, 111, 128
Fatigue syndrome, 149–150
Fat mass, 207
Fighting spirits, 219
Forkhead Box O3 (FOXO3), 69
Fresh Start Trial, 223
Functional Assessment of Cancer Therapy (FACT), 201
Functional Assessment of Cancer Therapy-Fatigue Module (FACT-F), 128

G
Gastric cancer, 87–88
Gastrointestinal tract tumors, 148–149
Glucose transporter type 4 (GLUT4) protein, 75
Gluta redoxin (GRX), 12
Glutathione peroxidase (GPX), 11
Graft-versus-host diseases (GVHD), 120
Graft-versus-leukemia (GVL), 120
Graft-versus-tumor-effect, 120
Growth factors, 22, 26 See also Insulin like-growth factor (IGF) system
Gynecologic tumors, 147–148

H
Hematopoietic stem-cell transplantation (HSCT), 161, 166
allo-HSCT, 120
auto-HSCT, 120
GVL effect, 120
physical activity and epidemiological data, 121
exercise trials, 122–125
hematological/immunological parameters, 127
Hematopoietic stem-cell transplantation (HSCT) (cont.)
physiological/functional adaptations, 122, 126–127
psychosocial parameters
contraindications, 138
current exercise recommendations, 137
fatigue, 128
five symptom clusters, 129
future prospects, 138–139
non-randomized controlled trials, 129, 134–135
QoL, 127–128
randomized controlled trials, 129–133
study outcomes, 136–137
vigor improvement, 129
treatment-related problems, 120–121
uses and variations, 119–120
Histamine, 39
Hormones, 22, 26 See also Sex steroid hormones
Humoral immune response, 39

I
IGF-1 binding protein (IGFBP-3), 26, 29–30
Immune regulation and exercise
acute exercise
macrophage function and, 44
NK cell function and, 45
t-cell function and, 46–47
anti-tumor immunity, 48–49
chronic exercise
macrophage function and, 44–45
NK cell function and, 46
t-cell function and, 47–48
future prospects, 50
human and animal exercise protocols, 42–43
immune system
anti-tumor effector mechanisms, 40–41
cytotoxicity, 40
innate and adaptive immunity, 39
macrophages, 41
TAMs, 41–42
tumor elimination phase, 40
physical activity and cancer prevention, 38
Immunosurveillance, 40, 42
Induction stage, 162
Inflammation, 39, 42
Inflammatory mediators, 38, 43
Innate immunity, 39
Insulin, 27–29
Insulin-like-growth factor (IGF)-1, 92–93
Insulin like-growth factor (IGF) system, 29–30
Insulin resistance, 22, 25, 74–75, 87, 90
Intensification, 162
Interferon, 39
Interferon-γ (IFN-γ), 40
Interleukin-4 (IL-4), 40, 41
Interleukin-5 (IL-5), 40
Interleukin-6 (IL-6), 24, 32, 62, 67
Interleukin-1β (IL-1β), 22

L
Lean body mass, 22
Lean body mass (LBM), 185, 188, 207
Leisure time physical activity, 86
Leptin, 23–24
Leucine, 186, 191
α-Lipoic acid and bilirubin, 12
Lung and respiratory tract tumors, 146–147
Lung cancer, 95–96, 113
Lymphedema, 111, 209–210
Lysozymes, 39

M
Macrophage phagocytosis, 42, 44
Maintenance, 162
Major histocompatibility complex (MHC), 40
Mammalian target of rapamycin (mTOR), 66
Mast cells, 39
Metabolic equivalent task (MET), 62, 190
Mitochondria, 9–10
M1macrophages, 41, 42
Multi-agent chemotherapy, 161, 162
Multidimensional Fatigue Inventory, 128
Multiple-Hit hypothesis, 109
Muscle protein degradation, 60, 69
Muscle wasting, 68, 73
Myofibrillar protein, 66

N
National Cancer Institute (NCI), 2
National Center for Tumor Diseases (NCT), 2
National Health and Nutrition Examination Survey (NHANES), 217
Natural killer (NK) cell, 45, 46
Natural killer cell cytotoxicity (NKCC), 45
Nitric oxide synthases (NOS), 9
Nitro oxide, 9, 10
Non-Hodgkin lymphoma (NHL), 164
Nuclear transcription factor erythroid 2p45-related factor 2 (Nrf2), 16
Nurses’ Health Study, 190
O
Occupational physical activity, 87, 88, 95
Optic atrophy protein 1 (OPA1), 72
Ovarian cancer, 91–92
Overall survival, 210–211
Oxidative damage, 10, 12
Oxidative stress, 12, 16

P
Palliative medicine
aerobic and muscle strength interventions, 145
common symptoms, 144, 145
curative and palliative treatment setting, 151
definition, 144
disease progression and, 144
gastrointestinal tract tumors, 148–149
gynecologic tumors, 147–148
lung and respiratory tract tumors, 146–147
pathophysiological implications
anorexia-cachexia syndrome, 152
dropout rates, 150
exercise interventions, 150
fatigue syndrome, 149–150
severe pain syndrome, 152
physical activity and exercise recommendations, 152–153
physical and emotional effects, 151–152
prostate cancer, 147
SOPC model, 144
Pancreatic cancer, 88
Patient’s status of fatigue
(POMS subscales), 128
Peak oxygen consumption (VO_{2peak}), 206–207
Pediatric cancer treatment
ALL, 161–162
cancer prevalence, 159–160
childhood v.s. adult cancer, 160
CNS tumors, 163
exercise and, 159–161
hematological malignancies, 162–163
in-hospital gymnasium, 171–172
NHL, 164
physical activity
children not undergoing HSCT, 169–170
children undergoing HSCT, 170
safety, 172–173
solid tumors, 171
renal (Wilms) tumors, 163–164
side effects and physical function
cancer fatigue, 166–167
eye and late, 164–166
HSCT, 166
PA and fitness levels, 167–168
soft tissue sarcomas, 163
survival rates, 160
types, 161
Perforin, 40, 41
Peroxiredoxin (PRX), 12
Phagocytosis, 44
Phospholipase A₂, 10
Phospho enol pyruvate carboxy kinase (PEPCK), 24
Physical activity (PA), 8
breast cancer, 89–90
decidual cancer, 90–91
epidemiologic evidence, 96–97
gastrointestinal cancer
colon and rectal cancer, 85–87
gastric cancer, 87–88
pancreatic cancer, 88
genitourinary cancer
bladder cancer, 94
lung cancer, 95–96
prostate cancer, 92–93
renal cell cancer, 93
testicular cancer, 94–95
HSCT and
epidemiological data, 121
exercise trials, 122–125
hematological/immunological parameters, 127
physiological/functional adaptations, 122, 126–127
methodologic issues, 84–85
methods, 84
outcomes, 99
ovarian cancer, 91–92
pediatric cancer treatment
children not undergoing HSCT, 169–170
children undergoing HSCT, 170
safety, 172–173
solid tumors, 171
proposed biologic mechanism, 98
public health impact and guidelines, 96
Physical Activity and Lymphedema (PAL) trial, 209
Post diagnosis weight gain, 183
Primary cancer prevention. See Physical activity (PA)
Prostaglandin E₂, 87
Prostate cancer, 92–93, 147, 188–189,
202, 205
Q
Quality of life (QOL), 22, 111, 112, 161
breast cancer related effects, 203
efficacy improvement, 201–202
FACT survey, 201
influence of attention, 202–203
outcomes and future prospects, 203–204
yoga and, 203

R
Reactive oxygen species (ROS) and reactive
nitrogen species (RNS)
cancer cell metastasis, 16
carcinogenesis pathway, 14–15
enzymes involved, 10, 11
hydrogen peroxide, 8–9
hyperchlorite, 9
mitochondria, 9–10
NAD(P)H oxidase enzymes, 10
NF-KB activation and COX-2 expression,
16
nitric oxide, 9
NOS, 10
Nrf2, 16
phospholipase A2, 10
pro carcinogens, 15
superoxide, 8
tissues involved, 9
xanthine oxidase, 10
Recreational physical activity, 88, 95
Reinduction, 162
Renal cell cancer (RCC), 93
Renal (Wilms) tumors, 163–164
Reserve capacity, 109
Resistance exercise. See Aerobic and
resistance exercise, cancer survivors
Resistance training, 202, 203
Risk reduction
breast cancer, 89–90
colon and rectal cancer, 85–87
gastric cancer, 95
lung cancer, 90–91
ovarian cancer, 91–92
pancreatic cancer, 88
prostate cancer, 92

Sarcopenia, 185, 186
Self-efficacy, 139, 220
Sex steroid hormones, 30–31
Social cognitive theory (SCT), 219–220
Soft tissue sarcomas, 163
Specialized outpatient palliative care (SOPC)
model, 144
Superoxide, 8
Superoxide dismutase (SOD), 11

T
T cell cytokine, 47
Testicular cancer, 94–95
Theory of planned behavior (TPB), 219–220
Thioredoxin (TRX), 12
T lymphocyte, 40, 41
TNF-related apoptosis-inducing ligand
(TRAIL)-mediated killing, 40
Toll-like receptors, 41
Treadmill test, 111
Treatments side effects. See Pediatric cancer
treatment
Tumor-associated macrophages (TAMs), 41–42
Tumor elimination, 40
Tumor escape, 40
Tumor growth
cellular antioxidant defense systems
distribution, 12–13
exercise-induced changes, 13–14
GPX, 11
GRX, 12
α-lipoic acid and bilirubin, 12
PRX, 12
SOD, 11
TRX, 12
uric acid, 12
exercise and, 8
molecular mechanisms, 8
ROS and RNS (see Reactive oxygen
species (ROS) and reactive nitrogen
species (RNS))
Tumor-immune cell equilibrium, 40
Tumor infiltrating lymphocytes (TILs), 40
Tumor necrosis factor alpha (TNFα), 22, 23
Type 1 CD4+ T cells (Th1 Cells), 40
Type II CD4+ T Cells (Th2 Cells), 40

U
Ubiquitine proteasome pathway, 69, 75
Unintentional weight loss, 60
Unpaired electrons, 8
Index

V
VO_{2\text{max}} 202

W
Weight management
  biologic mechanisms, 183
  breast cancer, 183–184
  diet and exercise trial, 184
  energy restricted diets, 185

prevalence, 182
Weight Watchers®, 184
program, 184
WINS, 184–185
Women’s Intervention Nutrition Study
  (WINS), 184–185

X
Xanthine oxidase, 10